FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380853410> ?p ?o ?g. }

• W4380853410 endingPage "9" @default.
• W4380853410 startingPage "1" @default.
• W4380853410 abstract "<b><i>Introduction:</i></b> Ustekinumab (UST) has been approved for the treatment of moderate-to-severe ulcerative colitis (UC). Real-world data showing the effectiveness and safety of UST are necessary to confirm the results of clinical trials for applicability in daily clinical practice. Although some studies have reported real-world evidence of UST, only few studies have confirmed its effectiveness in the real world. The aim of this study was to assess the short- and long-term effectiveness, durability, safety, and risk factors for discontinuation of UST in UC in clinical practice. <b><i>Methods:</i></b> This was a retrospective, single-center, observational study. From March 2020 to January 2023, all consecutive patients with active UC who were treated with UST at Nagoya University Hospital were included. The primary outcome was the clinical remission rate at weeks 2–8 and weeks 24–48. The secondary outcomes included clinical response, persistence of UST therapy, endoscopic changes during follow-up, risk factors for UST discontinuation, and occurrence of any adverse events. The clinical effectiveness was evaluated using the Lichtiger score. <b><i>Results:</i></b> A total of 31 patients were included in this study. The clinical remission rates were 9.7%, 29.0%, 54.8%, and 64.5% at weeks 2, 8, 24, and 48, respectively. Twelve (38.7%) patients discontinued UST during the follow-up period. The probability of continuing UST was 93.5%, 80.6%, 77%, and 70% at weeks 2, 8, 24, and 48, respectively. The major reason for discontinuation of UST was primary failure (75.0%). A high baseline C-reactive protein (CRP) level was a significant risk factor for the discontinuation of UST. No adverse events were observed in this study. <b><i>Conclusion:</i></b> UST is effective for patients with UC. High CRP levels were identified as a risk factor for UST discontinuation. The findings of this study would help clinicians to select appropriate treatment options for patients with UC by identifying the risk factors for treatment discontinuation." @default.
• W4380853410 created "2023-06-16" @default.
• W4380853410 creator A5007617963 @default.
• W4380853410 creator A5009069198 @default.
• W4380853410 creator A5018627221 @default.
• W4380853410 creator A5023038231 @default.
• W4380853410 creator A5041123163 @default.
• W4380853410 creator A5048247150 @default.
• W4380853410 creator A5048443511 @default.
• W4380853410 creator A5051339038 @default.
• W4380853410 creator A5060266231 @default.
• W4380853410 creator A5065828661 @default.
• W4380853410 creator A5067050108 @default.
• W4380853410 creator A5071636090 @default.
• W4380853410 creator A5073948929 @default.
• W4380853410 creator A5074762441 @default.
• W4380853410 creator A5090551412 @default.
• W4380853410 date "2023-06-14" @default.
• W4380853410 modified "2023-09-27" @default.
• W4380853410 title "Real-world Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis" @default.
• W4380853410 doi "https://doi.org/10.1159/000531497" @default.
• W4380853410 hasPublicationYear "2023" @default.
• W4380853410 type Work @default.
• W4380853410 citedByCount "0" @default.
• W4380853410 crossrefType "journal-article" @default.
• W4380853410 hasAuthorship W4380853410A5007617963 @default.
• W4380853410 hasAuthorship W4380853410A5009069198 @default.
• W4380853410 hasAuthorship W4380853410A5018627221 @default.
• W4380853410 hasAuthorship W4380853410A5023038231 @default.
• W4380853410 hasAuthorship W4380853410A5041123163 @default.
• W4380853410 hasAuthorship W4380853410A5048247150 @default.
• W4380853410 hasAuthorship W4380853410A5048443511 @default.
• W4380853410 hasAuthorship W4380853410A5051339038 @default.
• W4380853410 hasAuthorship W4380853410A5060266231 @default.
• W4380853410 hasAuthorship W4380853410A5065828661 @default.
• W4380853410 hasAuthorship W4380853410A5067050108 @default.
• W4380853410 hasAuthorship W4380853410A5071636090 @default.
• W4380853410 hasAuthorship W4380853410A5073948929 @default.
• W4380853410 hasAuthorship W4380853410A5074762441 @default.
• W4380853410 hasAuthorship W4380853410A5090551412 @default.
• W4380853410 hasBestOaLocation W43808534101 @default.
• W4380853410 hasConcept C126322002 @default.
• W4380853410 hasConcept C167135981 @default.
• W4380853410 hasConcept C197934379 @default.
• W4380853410 hasConcept C23131810 @default.
• W4380853410 hasConcept C2778715236 @default.
• W4380853410 hasConcept C2778975655 @default.
• W4380853410 hasConcept C2779134260 @default.
• W4380853410 hasConcept C2780132546 @default.
• W4380853410 hasConcept C2780479503 @default.
• W4380853410 hasConcept C535046627 @default.
• W4380853410 hasConcept C71924100 @default.
• W4380853410 hasConceptScore W4380853410C126322002 @default.
• W4380853410 hasConceptScore W4380853410C167135981 @default.
• W4380853410 hasConceptScore W4380853410C197934379 @default.
• W4380853410 hasConceptScore W4380853410C23131810 @default.
• W4380853410 hasConceptScore W4380853410C2778715236 @default.
• W4380853410 hasConceptScore W4380853410C2778975655 @default.
• W4380853410 hasConceptScore W4380853410C2779134260 @default.
• W4380853410 hasConceptScore W4380853410C2780132546 @default.
• W4380853410 hasConceptScore W4380853410C2780479503 @default.
• W4380853410 hasConceptScore W4380853410C535046627 @default.
• W4380853410 hasConceptScore W4380853410C71924100 @default.
• W4380853410 hasLocation W43808534101 @default.
• W4380853410 hasOpenAccess W4380853410 @default.
• W4380853410 hasPrimaryLocation W43808534101 @default.
• W4380853410 hasRelatedWork W2086156447 @default.
• W4380853410 hasRelatedWork W2464962541 @default.
• W4380853410 hasRelatedWork W2475104063 @default.
• W4380853410 hasRelatedWork W2896381073 @default.
• W4380853410 hasRelatedWork W3043529833 @default.
• W4380853410 hasRelatedWork W3183680366 @default.
• W4380853410 hasRelatedWork W3195932509 @default.
• W4380853410 hasRelatedWork W4311359465 @default.
• W4380853410 hasRelatedWork W4318478878 @default.
• W4380853410 hasRelatedWork W4360600172 @default.
• W4380853410 isParatext "false" @default.
• W4380853410 isRetracted "false" @default.
• W4380853410 workType "article" @default.